White House looks for path to provide experimental Ebola drugs to infected patients

Drugmakers who sell unapproved drugs are generally setting themselves up for big penalties from federal authorities. The Obama administration, under mounting pressure, intends to craft a policy for using experimental drugs to treat the Ebola virus, Reuters reports. The White House Friday said it is setting up a working group to consider the use of drugs on the hundreds patients in Africa infected by the deadly virus, which has killed nearly 1,000 so far. The FDA already allowed an experimental drug from California-based Mapp Biopharmaceutical to be used to treat two U.S. aid workers who became infected. But any accelerated use of the drugs poses potential threats to patients and the drugmakers, so a policy and pathway to use will have to be designed carefully. Story | More

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.